News

DOACs Associated With High Bleeding Rates, VTEs, ATEs in MPNs

11/09/2021

Novel clinical data from a multicenter retrospective analysis evaluates the safety of direct oral anticoagulant efficacy in patients with MPNs; these findings were presented at the 2021 Annual ASH Meeting.

Novel clinical data from a...

11/09/2021

Oncology

News

JAKi Therapy Yields Safe and Effective Results in Portal Hypertensive MPNs

11/08/2021

Results from an observational study were presented at the 2021 Annual ASH Meeting to demonstrate JAKi therapy as safe and effective in portal hypertensive patients with MPNs.

Results from an observational...

11/08/2021

Oncology

News

ASXL1 Mutation Identified as High-Risk Bleeding Factor in MPN

11/08/2021

Findings from a retrospective analysis were shared at the 2021 Annual ASH Meeting on novel bleeding risk factors in MPNs that can prevent surgical complications when identified, including the ASXL1 mutation.

Findings from a retrospective...

11/08/2021

Oncology

News

Triplet Combo Effective Conditioning Regimen for Patients With AML, MDS, or MPNs

10/28/2021

A study on treosulfan, fludarabine, and cytarabine found the combination provided tolerable, feasible, and effective conditioning for patients with AML, MDS, or MPNs.

A study on treosulfan,...

10/28/2021

Oncology

News

Quizartinib-Based Combos Improve Outcomes in AML, MDS

10/08/2021

Phase 1/2 study findings demonstrate the clinical efficacy of quizartinib plus azacitidine or low-dose cytarabine for the treatment of patients with AML or MDS.

Phase 1/2 study findings...

10/08/2021

Oncology

News

Venetoclax Plus Chemotherapy Improves OS in Patients With AML, MDS

08/23/2021

Findings from thee Phase 2 CLIA study shows the safety and activity of venetoclax plus chemotherapy in AML or MDS.

Findings from thee Phase 2 CLIA...

08/23/2021

Oncology

News

First-Line Fedratinib Improves PFS in Patients With MF

08/04/2021

Study findings suggest that first-line fedratinib significantly improves PFS compared with placebo in patients with MF.

Study findings suggest that...

08/04/2021

Oncology

Conference Insider

Venetoclax–Azacitidine Improves OS Over Azacitidine Alone in Treatment-Naïve Patients With tMN, A-MDS/MPNs

06/23/2021

Hina M. Porcelli

According to data presented at ASCO 2021, venetoclax plus azacitidine improved survival over azacitidine alone in treatment-naïve patients with tMN and antecedent MDS or MPNs.

According to data presented at...

06/23/2021

Oncology

News

Azacitidine Improves RBC-TI Rates in Patients with Lower-Risk MDS

04/23/2021

Oral azacitidine significantly improved RBC-TI rates and induced durable bilineage improvements in patients with lower-risk MDS and high-risk disease features, according to a phase 3 trial.

Oral azacitidine significantly...

04/23/2021

Oncology

News

Decitabine With or Without Ruxolitinib Shows Benefit in Advanced Phases of MPN

03/29/2021

When initiated early in the course of the disease, decitabine with or without ruxolitinib has shown clinical benefit in patients with advanced phases of MPNs.

When initiated early in the...

03/29/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology